Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients

University of Verona

Status: Completed

Conditions: Hypercholesterolemia

Treatments: Procedure: LDL-apheresis

Study type: Observational

Funder types: Other

Identifiers

NCT01678521

MZentiPTX3

Details and patient eligibility

About

Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional pattern-recognition protein, is expressed in many tissues/cells, including innate immunity cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and future cardiovascular risk.

LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis on plasma PTX3 levels.

Full description

Hypercholesterolemic patients with documented CAD, on chronic fortnightly LDL-apheresis treatment will be enrolled in this study.

Blood samples will be collected before and after a single LDL-Apheresis treatment to asses PTX3, HsCRP, IL6, IL10, Fibrinogen and lipid plasma levels.

Enrollment: 12 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypercholesterolemia
• documented CAD
• chronic LDL-apheresis treatment

Exclusion criteria

• mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Trial design

12 participants in 1 patient group

Hypercholesterolemic patients

Description:

Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment

Treatment:

Procedure: LDL-apheresis